ClinicalTrials.gg
CompletedNCT07486141Updated Oct 30, 2026

Effect of Vitamin D and Folic Acid on Mild Cognitive Impairment

An interventional study of Vitamin D3 (800 IU/d) and Folic Acid(0.4mg/d) and Vitamin D3 (1600 IU/d) and Folic Acid(0.4mg/d) in Mild Cognitive Impairment, sponsored by Capital Medical University. Completed at 1 site in China. Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Capital Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Nov 2024, registered Mar 2026).
Updated Oct 30, 2026Now CompletedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 310 studies in Cognitive Dysfunction with a site in China — 144 open to participants now, 156 under way, 8 of them phase 3. Cognitive Dysfunction · China.

Enrollment
25th of 191
380 · median 110
Started
2024
with 44 others
No phase
139 of 310
61 open now
Registered
264th of 310
by date

Among the 310 studies in Cognitive Dysfunction with a site in China, this one is the 25th largest by enrollment of the 191 interventional ones that give a count, is one of 45 that started in 2024, is one of 139 with no phase, and was the 264th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

144 of the 310 studies in Cognitive Dysfunction with a site in China are open now. Recruiting first, the newest first:

139 more — sign in →

All 144 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 50 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 310 studies in Cognitive Dysfunction with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the effects of Vitamin D3 combined with Folic Acid on mild cognitive impairment (MCI). Participants aged 50 to 70 years with MCI will be randomly assigned to three groups: a low-dose Vitamin D3 plus Folic Acid group, a high-dose Vitamin D3 plus Folic Acid group, and a placebo group. The intervention will last for 6 months. The main goal is to observe whether this nutritional intervention can improve or delay the decline of cognitive function.

Read the detailed description

Mild cognitive impairment (MCI) is a critical transitional stage between normal aging and Alzheimer's disease (AD). Designing precise dietary and nutritional interventions is a vital strategy for preventing and treating MCI. Based on an established cohort study, this randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy of combining Vitamin D3 and Folic Acid in MCI patients.

The study will analyze changes in overall and multi-dimensional cognitive functions before and after the 6-month intervention. Furthermore, the study will explore the underlying mechanisms by analyzing biological samples (blood, urine, and feces) for alterations in 27-hydroxycholesterol (27-OHC) and its metabolites, active Vitamin D3, Folic Acid levels, CYP27A1 activity, and related gene polymorphisms. The findings will help determine the optimal interaction ratio and effective dosage of this combined nutritional intervention for delaying cognitive decline.

03

Conditions studied

  • Mild Cognitive Impairment

Keywords

  • Vitamin D
  • Folic Acid
04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 50 to 70 years old.
  • Derived from the established elderly chronic disease and health cohort.
  • Meet the diagnostic criteria for Mild Cognitive Impairment (MCI) (e.g., indicated by specific cut-off scores on the adjusted for education level).
  • Volunteered to participate, able to cooperate with the cognitive assessments, and signed the form.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of Alzheimer's disease, other types of dementia, or severe psychiatric disorders (e.g., severe depression, schizophrenia).
  • History of severe neurological diseases (e.g., stroke, brain tumor, brain trauma) that may affect cognitive function.
  • Severe visual or hearing impairments that prevent the completion of cognitive tests.
  • Patients with liver diseases (e.g., hepatitis, liver cirrhosis) or kidney diseases (e.g., nephritis, kidney stones, renal failure).
  • Patients with hypercalcemia (serum calcium concentration > 10.5 mg/dl).
  • Patients with severe anemia, severe malnutrition, or abnormal thyroid function.
  • Current use or use within the past 3 months of cognition-improving drugs, Vitamin D, or Folic Acid supplements, and unwilling to undergo a 3-month prior to the intervention.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
380 participants (actual)

Study arms

  • Experimental
    800IU/d Vitamin D3 + Folic Acid

    Participants will receive one folic acid(0.4mg/d) tablet and one low-dose(800IU/d) Vitamin D3 tablet orally once daily at breakfast for 6 months.

    Dietary Supplement: Vitamin D3 (800 IU/d) and Folic Acid(0.4mg/d)

  • Experimental
    1600IU/d Vitamin D3 + Folic Acid

    Participants will receive one folic acid(0.4mg/d) tablet and one high-dose(1600IU/d) Vitamin D3 tablet orally once daily at breakfast for 6 months.

    Dietary Supplement: Vitamin D3 (1600 IU/d) and Folic Acid(0.4mg/d)

  • Placebo comparator
    Placebo

    Participants will receive two starch placebo tablets (identical in appearance, color, and smell to the active supplements) orally once daily at breakfast for 6 months.

    Other: Starch Placebo

Interventions

  • Dietary supplementVitamin D3 (800 IU/d) and Folic Acid(0.4mg/d)

    Drug pages: CholecalciferolStudies of CholecalciferolCholecalciferol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Folic AcidStudies of Folic AcidFolic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    One folic acid tablet and one low-dose Vitamin D3 tablet administered orally once daily at breakfast for 6 months.

  • Dietary supplementVitamin D3 (1600 IU/d) and Folic Acid(0.4mg/d)

    Drug pages: CholecalciferolStudies of CholecalciferolCholecalciferol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Folic AcidStudies of Folic AcidFolic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    One folic acid tablet and one high-dose Vitamin D3 tablet administered orally once daily at breakfast for 6 months.

  • OtherStarch Placebo

    Two starch placebo tablets administered orally once daily at breakfast for 6 months. The placebo is identical in appearance, color, and smell to the active tablets.

06

What researchers measure

Primary outcomes

  1. Change in Global Cognitive Function Assessed by Montreal Cognitive Assessment (MoCA) Score

    Global cognitive function is evaluated using the Montreal Cognitive Assessment (MoCA). The MoCA assesses different cognitive domains including attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. The total score ranges from 0 to 30. Higher scores indicate better cognitive performance.

    Time frame: Baseline and 6 months

Secondary outcomes

  1. Change in Serum 25-hydroxyvitamin D [25(OH)D] Levels

    Serum concentrations of 25(OH)D will be measured to assess the response to Vitamin D3 supplementation.

    Time frame: Baseline and 6 months

  2. Change in Serum Folic Acid Levels

    Serum concentrations of folic acid will be measured to assess the response to folic acid supplementation.

    Time frame: Baseline and 6 months

  3. Change in 27-hydroxycholesterol (27-OHC) Levels

    Levels of 27-OHC and its metabolites in biological samples (blood/urine/feces) will be measured to explore the underlying metabolic mechanisms.

    Time frame: Baseline and 6 months

07

Study locations

1 site
  • Capital Medical University
    Beijing, Beijing Municipality 100069, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Apr 2026, 17 months.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's 17 months is below that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2026
First posted
Mar 20, 2026
StartActual
Nov 1, 2024
Primary completionActual
Apr 1, 2026
CompletionActual
Jun 1, 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Active, not recruiting→Completed
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07486141
Responsible party
Jiaxuan Tao (Doctoral student, Capital Medical University) — Principal investigator
First posted
Mar 20, 2026
Start date
Nov 1, 2024
Primary completion
Apr 1, 2026
Completion
Jun 1, 2026
Last update
Oct 30, 2026

Study contacts

Rong Xiao, PhD
principal investigator · Capital Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cholecalciferol · Folic Acid

Start the discussion